Rituximab found as effective as cyclophosphamide in AAV children

People with ANCA-associated vasculitis (AAV) have a higher frequency of thyroid diseases, that is, those that affect the hormone-production function of the thyroid gland, than the general population, a study in China suggests. Being female, having coronary artery disease, which is marked by reduced blood flow in the arteries…

Low blood levels of glial fibrillary acidic protein (GFAP) are linked to more active disease and a higher risk of kidney failure in newly diagnosed ANCA-associated vasculitis (AAV), a study finds. The findings point to GFAP as a potential blood biomarker to predict the course of AAV early and…

Self-reactive antibodies, or autoantibodies, against two proteins — homeostatic iron regulator, or HFE, and synaptotagmin 5, known as SYT5 — appear to be linked to a higher risk of relapse among people with ANCA-associated vasculitis (AAV), according to a new study. These findings suggest that the presence of abnormal…

A new Phase 3 clinical trial is recruiting children and adolescents with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), the most common types of ANCA-associated vasculitis (AAV), to test Tavneos (avacopan) in combination with rituximab or cyclophosphamide. That’s according to a financial update released by…

Fasenra (benralizumab) has been granted approval in the European Union as an add-on treatment for adults with relapsing or treatment-resistant eosinophilic granulomatosis with polyangiitis, or EGPA, a rare type of ANCA-associated vasculitis (AAV). The clearance of Fasenra, “with its convenient, single-monthly injection is a positive step forward…

Combination maintenance therapy with Nucala (mepolizumab) and azathioprine may be more effective than either treatment alone at maintaining disease remission and reducing the need for glucocorticoids in people with severe eosinophilic granulomatosis with polyangiitis (EGPA). These are the findings of a single-center study in Japan that support the use…

Alivexis’ experimental oral therapy MOD06051, designed to suppress an underlying mechanism of ANCA-associated vasculitis (AAV), eased blood vessel inflammation and tissue damage in a rat model of the disease, a study from Japan found. In lab-grown human and rat cells, the therapy was shown to block the activity…

Low blood levels of the copper-carrying protein ceruloplasmin at diagnosis are associated with worse survival in adults with ANCA-associated vasculitis (AAV) who test positive for self-reactive antibodies against the myeloperoxidase (MPO) enzyme, a new study from France has shown. “This is the first study associating low [blood] ceruloplasmin level…

ADX-097, an experimental tissue-targeted therapy that Q32 Bio is developing for ANCA-associated vasculitis (AAV) and other diseases marked by overactivity of the immune complement system, was well tolerated in a Phase 1 clinical trial involving healthy volunteers. The study’s data also indicated that ADX-097 showed a favorable pharmacological…